Paushak is India’s largest phosgene based specialty chemicals manufacturer serving pharmaceutical, agrochemical and performance industries. Paushak is part of the Alembic group of companies situated in Gujarat, India.. Alembic Ltd is the oldest pharmaceutical company in India founded in 1907.
The company possesses a narrow moat derived from regulatory licenses and high switching costs associated with phosgene-based chemistry, which requires specialized safety infrastructure and stringent environmental permits. While net margins are high at 22.3%, the lack of durable pricing power is evident as margins contracted in FY26 due to an inability to pass on raw material spikes and pressure from Chinese imports.
Management has focused heavily on internal reinvestment, specifically a large-scale modernization and capacity expansion project slated for completion in FY26. While ROCE is healthy at 20%, the recent EPS CAGR of 3.7% lags revenue growth, suggesting that recent capital deployment has yet to translate into incremental per-share earnings growth.
The investment failed because the massive capacity expansion completed in FY26 coincided with a structural downturn in global commodity prices and intensified Chinese dumping, leaving the company with high fixed costs and idle assets. The 7.5x increase in borrowing limits, which seemed like prudent preparation, became a noose as interest coverage collapsed during a period of sustained margin compression. Management's inability to translate revenue into EPS growth proved to be a permanent feature rather than a temporary lag, as the specialized phosgene moat was bypassed by cheaper, non-phosgene chemical alternatives, rendering the expensive new infrastructure obsolete.
RichFakir rates Paushak Ltd's business quality as decent — 67/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Paushak Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Paushak Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Paushak Ltd's fair value is about ₹280 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →